These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15158636)

  • 1. Drug intervention trials in sepsis: divergent results.
    Polderman KH; Girbes AR
    Lancet; 2004 May; 363(9422):1721-3. PubMed ID: 15158636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for severe sepsis and septic shock.
    Sharma VK; Dellinger RP
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):395-403. PubMed ID: 16771617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation inhibitors in the treatment of sepsis.
    Freeman BD; Buchman TG
    Expert Opin Investig Drugs; 2002 Jan; 11(1):69-74. PubMed ID: 11772322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
    Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
    Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current management of septic shock.
    Russel JA
    Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis.
    Freeman BD; Zehnbauer BA; Buchman TG
    Shock; 2003 Jul; 20(1):5-9. PubMed ID: 12813361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and coagulation: implications for the septic patient.
    Dellinger RP
    Clin Infect Dis; 2003 May; 36(10):1259-65. PubMed ID: 12746771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing mortality in severe sepsis and septic shock.
    Levinson AT; Casserly BP; Levy MM
    Semin Respir Crit Care Med; 2011 Apr; 32(2):195-205. PubMed ID: 21506056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
    Balk RA
    Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [C-reactive protein concentrations during initial (empiric) treatment of neonatal sepsis].
    Janković B; Pasić S; Marković M; Veljković D; Milicić M
    Srp Arh Celok Lek; 2001; 129 Suppl 1():17-22. PubMed ID: 15637985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of sepsis.
    Girbes AR; Beishuizen A; Strack van Schijndel RJ
    Fundam Clin Pharmacol; 2008 Aug; 22(4):355-61. PubMed ID: 18705746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin replacement in patients with sepsis and septic shock.
    Giudici D; Baudo F; Palareti G; Ravizza A; Ridolfi L; D' Angelo A
    Haematologica; 1999 May; 84(5):452-60. PubMed ID: 10329925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacotherapy of sepsis].
    Guzzo I; Morabito S; Stucchi R; Poli G; Fumagalli R
    G Ital Nefrol; 2006; 23 Suppl 36():S79-86. PubMed ID: 17068734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Are there certified indications for the use of antithrombin III in intensive care].
    Kulka PJ; Tryba M; Lange S
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Mar; 36(3):143-53. PubMed ID: 11324345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation in sepsis: state of the art and future perspective.
    Antonopoulou A; Giamarellos-Bourboulis EJ
    Immunotherapy; 2011 Jan; 3(1):117-28. PubMed ID: 21174562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of protein C concentrate in pediatric patients with sepsis.
    Silvani P; Camporesi A; Licari E; Wolfler A
    Minerva Anestesiol; 2005 Jun; 71(6):373-8. PubMed ID: 15886604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antithrombin therapy of no value in sepsis according to a large clinical trial].
    Gårdlund B
    Lakartidningen; 2002 Mar; 99(13):1456-7, 1460. PubMed ID: 11989356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urosepsis: from the intensive care viewpoint.
    Marx G; Reinhart K
    Int J Antimicrob Agents; 2008 Feb; 31 Suppl 1():S79-84. PubMed ID: 18053691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.